TR201910410T4 - Endometriyal patolojilerde kök hücre terapisi. - Google Patents

Endometriyal patolojilerde kök hücre terapisi. Download PDF

Info

Publication number
TR201910410T4
TR201910410T4 TR2019/10410T TR201910410T TR201910410T4 TR 201910410 T4 TR201910410 T4 TR 201910410T4 TR 2019/10410 T TR2019/10410 T TR 2019/10410T TR 201910410 T TR201910410 T TR 201910410T TR 201910410 T4 TR201910410 T4 TR 201910410T4
Authority
TR
Turkey
Prior art keywords
endometrial
subject
bmdsc
autologous
stem cells
Prior art date
Application number
TR2019/10410T
Other languages
English (en)
Turkish (tr)
Inventor
SIMÓN Carlos
SANTAMARIA Javier
Pellicer Antonio
Cervello Irene
Original Assignee
Igenomix S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igenomix S L filed Critical Igenomix S L
Publication of TR201910410T4 publication Critical patent/TR201910410T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thermotherapy And Cooling Therapy Devices (AREA)
TR2019/10410T 2014-06-17 2015-06-05 Endometriyal patolojilerde kök hücre terapisi. TR201910410T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462013121P 2014-06-17 2014-06-17

Publications (1)

Publication Number Publication Date
TR201910410T4 true TR201910410T4 (tr) 2019-08-21

Family

ID=54329860

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/10410T TR201910410T4 (tr) 2014-06-17 2015-06-05 Endometriyal patolojilerde kök hücre terapisi.

Country Status (22)

Country Link
US (1) US11129851B2 (enExample)
EP (3) EP4012023B1 (enExample)
JP (2) JP6920062B2 (enExample)
CN (2) CN107073040A (enExample)
AU (1) AU2015275798B2 (enExample)
BR (1) BR112016029558A2 (enExample)
CA (1) CA2952559C (enExample)
CY (2) CY1122615T1 (enExample)
DK (2) DK3158057T3 (enExample)
ES (3) ES2910306T3 (enExample)
HR (3) HRP20240798T1 (enExample)
HU (3) HUE044823T2 (enExample)
LT (2) LT3569697T (enExample)
MX (1) MX377300B (enExample)
PL (3) PL3569697T3 (enExample)
PT (2) PT3158057T (enExample)
RS (3) RS63093B1 (enExample)
RU (1) RU2725006C2 (enExample)
SI (2) SI3569697T1 (enExample)
SM (3) SMT202200155T1 (enExample)
TR (1) TR201910410T4 (enExample)
WO (1) WO2015193737A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
EP3467124A1 (en) 2012-06-06 2019-04-10 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
JP6074049B2 (ja) 2012-10-12 2017-02-01 インバイオモーション エセ．エレ． ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
US11129851B2 (en) 2014-06-17 2021-09-28 Igenomix S.L. Stem cell therapy in endometrial pathologies
RU2771328C2 (ru) * 2016-06-23 2022-04-29 Титон Биотек, Инк. Клетки, экспрессирующие рецептор паратиреоидного гормона 1, и их применение
RU2699029C1 (ru) * 2018-12-10 2019-09-03 Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке
RU2741621C1 (ru) * 2020-09-25 2021-01-28 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ лечения внутриматочных синехий
WO2023003130A1 (ko) 2021-07-23 2023-01-26 차의과학대학교 산학협력단 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69027992D1 (de) 1989-05-05 1996-09-05 North Sydney Area Health Serv Steigerung der fruchtbarkeit
US6979533B2 (en) 1992-06-12 2005-12-27 The Trustees Of The University Of Pennsylvania Determination of endometrial receptivity toward embryo implantation
CA2203718A1 (en) 1997-04-25 1998-10-25 University Of British Columbia Cadherin-11 as an indicator of viable pregnancy
IL127896A0 (en) 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
EP1255851A4 (en) 2000-03-08 2004-03-31 Harvey J Kliman METHODS FOR DIAGNOSING AND MONITORING ENDOMETRIAL GLANDULAR DEVELOPMENT
EP1301195A2 (en) 2000-05-24 2003-04-16 Schering Aktiengesellschaft Pharmaceutical use of fibulin-1
US6780594B2 (en) 2000-09-25 2004-08-24 Schering Aktiengesellschaft Method for in vitro diagnosis of endometriosis
AUPR673001A0 (en) 2001-07-31 2001-08-23 Prince Henry's Institute Of Medical Research Pregnancy-related enzyme activity
DE10139874A1 (de) 2001-08-10 2003-04-30 Schering Ag Humane Mater-Proteine
GB0201284D0 (en) 2002-01-21 2002-03-06 Isis Innovation Screening methods for contraceptive and fertility agents
US20030186300A1 (en) 2002-03-20 2003-10-02 Ali Akoum Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions
EP1511863A4 (en) 2002-05-14 2006-12-27 Univ Leland Stanford Junior ENDOMETRIAL GENES FOR THE DETECTION OF ENDOMETRIAL DISORDERS
DE10236405A1 (de) 2002-08-02 2004-02-19 Schering Ag Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie
WO2004014935A1 (de) 2002-08-02 2004-02-19 Schering Aktiengesellschaft Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie
EP1579007B1 (de) 2002-12-21 2015-05-27 Universität Leipzig Verfahren und mittel zur bestimmung von bestimmten zuständen bzw. veränderungen im uterusepithel und im epithel anderer organe
US20060286555A1 (en) 2003-08-21 2006-12-21 Van Beuningen Marinus G J Microarray support for bioprobe synthesis
CN1863905A (zh) 2003-09-08 2006-11-15 得克萨斯系统大学董事会 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物
EP1670902A4 (en) 2003-09-08 2008-05-07 Univ Texas METHOD AND COMPOSITION FOR ENHANCING i IN VITRO /i EMBRYO DEVELOPMENT BY SUPPLEMENTING CULTURE MEDIUM WITH PROSTAGLANDIN OR A PROSTAGLANDIN ANALOG
ATE476525T1 (de) 2003-12-23 2010-08-15 Mount Sinai Hospital Corp Verfahren zum nachweis von mit endometrialer krankheit oder phase assoziierten markern
JP2008501035A (ja) 2004-05-28 2008-01-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 妊孕性関連障害の治療におけるｉｌ−１７の使用
EP2004242A2 (en) * 2006-03-31 2008-12-24 Koninklijke Philips Electronics N.V. Systems and methods for cell measurement utilizing ultrashort t2* relaxometry
JP2007278750A (ja) 2006-04-04 2007-10-25 Ono Pharmaceut Co Ltd プロスタグランジン類及びその類縁体の定量方法
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
GB0703683D0 (en) * 2007-02-26 2007-04-04 Ark Therapeutics Ltd The treatment of complications in pregnancy
US9259233B2 (en) * 2007-04-06 2016-02-16 Hologic, Inc. Method and device for distending a gynecological cavity
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
WO2010010201A1 (es) 2008-07-22 2010-01-28 Equipo Ivi Investigacion Sl Perfil de expresion genetica como marcador de la receptividad endometrial
WO2013166281A1 (en) * 2012-05-02 2013-11-07 Cedars-Sinai Medical Center Bi-functional compositions for targeting cells to diseased tissues and methods of using same
EP2348318A1 (en) 2010-01-21 2011-07-27 Equipo Ivi Investigación, S.L. Diagnostic method for endometrial receptivity
PT2768976T (pt) 2011-10-21 2018-04-05 Inst Nat Sante Rech Med Métodos para avaliar a receptividade endométrica de uma paciente após hiperestimulação ovárica controlada
CN111929133A (zh) 2011-11-30 2020-11-13 新加坡科技研究局 用于生物学检测的gm1神经节苷脂与膜联蛋白v的微粒多肽比例
SG11201407667UA (en) 2012-06-27 2015-02-27 Hoffmann La Roche MEANS AND METHODS APPLYING sFlt-1/PlGF OR ENDOGLIN/PlGF RATIO TO RULE-OUT ONSET OF PREECLAMPSIA WITHIN A CERTAIN TIME PERIOD
RU2515475C1 (ru) * 2012-11-15 2014-05-10 Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте
US20170097358A1 (en) 2014-03-21 2017-04-06 Igenomix S.L. Early detection of preeclampsia
US11129851B2 (en) 2014-06-17 2021-09-28 Igenomix S.L. Stem cell therapy in endometrial pathologies

Also Published As

Publication number Publication date
JP2020138984A (ja) 2020-09-03
ES2910306T3 (es) 2022-05-12
JP6920062B2 (ja) 2021-08-18
JP2017522288A (ja) 2017-08-10
PL3569697T3 (pl) 2022-07-04
EP3158057B1 (en) 2019-04-17
SMT202200155T1 (it) 2022-05-12
HRP20191240T1 (hr) 2019-11-01
SI3158057T1 (sl) 2019-10-30
EP3569697B8 (en) 2022-04-27
ES2736117T3 (es) 2019-12-26
WO2015193737A1 (en) 2015-12-23
PL3158057T3 (pl) 2020-05-18
AU2015275798A1 (en) 2017-02-02
CN107073040A (zh) 2017-08-18
BR112016029558A2 (pt) 2017-08-22
CY1125938T1 (el) 2024-02-16
PT3158057T (pt) 2019-07-19
HUE058328T2 (hu) 2022-07-28
RU2017101147A3 (enExample) 2019-02-06
DK3569697T3 (da) 2022-04-04
CN116747241A (zh) 2023-09-15
MX377300B (es) 2025-03-07
LT3569697T (lt) 2022-04-25
SMT202400270T1 (it) 2024-07-09
EP4012023A1 (en) 2022-06-15
AU2015275798B2 (en) 2021-03-25
EP4012023C0 (en) 2024-05-15
RS63093B1 (sr) 2022-04-29
HUE044823T2 (hu) 2019-11-28
HRP20220419T1 (hr) 2022-05-27
PT3569697T (pt) 2022-05-02
RU2017101147A (ru) 2018-07-17
LT3158057T (lt) 2019-09-25
RS65719B1 (sr) 2024-08-30
EP4012023B1 (en) 2024-05-15
CA2952559A1 (en) 2015-12-23
PL4012023T3 (pl) 2024-09-02
DK3158057T3 (da) 2019-07-29
CA2952559C (en) 2023-01-24
HRP20240798T1 (hr) 2024-09-27
ES2983444T3 (es) 2024-10-23
US11129851B2 (en) 2021-09-28
SI3569697T1 (sl) 2022-05-31
US20170128492A1 (en) 2017-05-11
MX2016016756A (es) 2017-11-02
RU2725006C2 (ru) 2020-06-29
EP3158057A1 (en) 2017-04-26
RS59210B1 (sr) 2019-10-31
CY1122615T1 (el) 2021-03-12
EP3569697A1 (en) 2019-11-20
HUE067463T2 (hu) 2024-10-28
SMT201900400T1 (it) 2019-09-09
EP3569697B1 (en) 2022-01-05

Similar Documents

Publication Publication Date Title
TR201910410T4 (tr) Endometriyal patolojilerde kök hücre terapisi.
Zhao et al. Exosomes derived from adipose mesenchymal stem cells restore functional endometrium in a rat model of intrauterine adhesions
Gharibeh et al. Cell-based therapy in thin endometrium and Asherman syndrome
Singh et al. Autologous stem cell transplantation in refractory Asherman's syndrome: a novel cell based therapy
Puente Gonzalo et al. Intrauterine infusion of platelet-rich plasma for severe Asherman syndrome: a cutting-edge approach
Aghajanova et al. Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience
Fan et al. Umbilical cord mesenchyme stem cell local intramuscular injection for treatment of uterine niche: Protocol for a prospective, randomized, double-blinded, placebo-controlled clinical trial
AU2016332771A1 (en) Pharmaceutical composition for improving ovarian function containing spheroid cell aggregate, and method for producing same
CN112870228B (zh) 一种多功能微环境保护外泌体水凝胶及其制备方法和应用
de Miguel‐Gómez et al. Strategies for managing Asherman's syndrome and endometrial atrophy: since the classical experimental models to the new bioengineering approach
KR102190883B1 (ko) 불임증의 처치에 사용되는 의약 조성물 및 그 제조 방법
HK40099394A (zh) 子宫内膜病理状况中的干细胞治疗
KR20140041263A (ko) 말초혈액 단핵세포를 유효성분으로 포함하는 예방 또는 치료용 약제학적 조성물
HK40075844A (en) Stem cell therapy in endometrial pathologies
HK40075844B (en) Stem cell therapy in endometrial pathologies
HK1242600A1 (en) Stem cell therapy in endometrial pathologies
Slattery et al. A new source of stem cells: mesenchymal stem cells from menstrual blood
Costa Stem cell therapy to approach refractory Asherman’s syndrome
Santamaria et al. Hysteroscopy and Stem Cell Therapy to Approach Refractory Asherman’s Syndrome
Seifer et al. Stem cell therapies for atrophic endometrium and Asherman's syndrome
Delis AMD3100 Administration for the Treatment of Asherman’s Syndrome in a Murine Model
de Miguel Gómez et al. Stem Cell Transplantation for Endometrial Regeneration in Humans
Petta et al. Natural killer cells and telomerase in the endometrium of patients with endometriosis
Hashish et al. Comparative Study Between the Differentiation Abilities of Placental Derived Stem Cells and Wharton Jelly Derived Stem Cells
Werkmeister Endometrial SUSD2+ Mesenchymal Stem/Stromal Cells in Tissue Engineering: Advances in Novel Cellular Constructs for Pelvic Organ Prolapse